InvestorsHub Logo
Followers 5
Posts 715
Boards Moderated 0
Alias Born 11/16/2022

Re: None

Friday, 06/16/2023 12:34:40 PM

Friday, June 16, 2023 12:34:40 PM

Post# of 463925
Who still believes the below headline from December 2022?! If you do ……! Seriously — never too late. Will help you think clearer.

7 months ahead — no meetings with FDA, zero progress/updates, zero clarification of the data inaccuracies and miscalculations. And, most convincingly, plans for full-approval replaced by AA based on NEW biomarker data (yet to see the light of the day).

Still believe the below? Sure — enjoy the bliss!

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,

SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE

https://www.anavex.com/post/anavex-2-73-blarcamesine-phase-2b-3-study-met-primary-and-key-secondary-endpoints
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News